Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus YUTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus YUTIQ.
HYDELTRASOL vs YUTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid